Early experience with the new endovascular aneurysm sealing system Nellix: First clinical results after 50 implantations.

OBJECTIVE: In the present study, 50 EVAS procedures were evaluated in regard to primary (survival and technical success) and secondary (device-related complications) events of interest. METHODS: The single center study was conducted from July 2013 to August 2014 with prospective collection of the clinical data. The clinical results were controlled by CT angiography and contrast-enhanced ultrasound. RESULTS: The technical success was 98% and the 30-day mortality 4%. One (2%) patient died from multisystem organ failure and another patient from an intracranial bleeding, respectively. One patient (2%) suffered from a device-related aneurysm rupture. During early follow-up, one (2%) patient developed an endoleak type II, while three (6%) patients suffered from a partial endograft limb thrombosis. Overall, a secondary intervention was necessary in six (12%) patients. CONCLUSIONS: With the Nellix EVAS system, a high primary technical success of 98% was achieved; one (2%) patient developed an endoleak type II which did not require secondary intervention. Those promising results are contrasted by a substantial rate of endograft limb thromboses (8%) and one (2%) intraoperative aneurysm rupture. Further studies are needed to assess the durability of the Nellix stentgraft and the occurrence of device-related complications.

Clinical outcomes in hybrid repair procedures for pathologies involving the aortic arch.

OBJECTIVE: Fifty patients with complex aortic disease, who received hybrid treatment of the aortic arch with supra-aortic debranching and endovascular stent-graft repair, were evaluated in regard to events of primary (survival and technical success) and secondary (procedure-related complications) interest. METHODS: The single-center study was conducted over an eight-year period from December 2004 to December 2012. Treated medical conditions included 23 aortic aneurysms (46%), 21 aortic dissections (42%), and six penetrating aortic ulcers (12%). Procedures were divided into groups of elective, urgent, and emergent. RESULTS: Twenty-eight (56%) patients were operated electively, 15 (30%) urgently, and seven (14%) emergently. Sternotomy, cardiopulmonary bypass, and deep hypothermic circulatory arrest were required in 12 (24%) patients. The primary technical success rate was 86% and raised to 92% (n=46) of secondary technical success rate after therapy of three type I endoleaks. The 30-day mortality added up to 16.0%, and the mean time of survival was 49.3 months. In a total of eight (16%) patients, an endoleak occurred (five endoleaks type I, three endoleaks type II), while nine (18%) of patients suffered a perioperative stroke. CONCLUSIONS: In severely ill patients with complex aortic diseases, hybrid therapy may offer a promising alternative to conventional open repair.

[Radiation exposure of staff during endovascular brachytherapy with Re-188 after PTA in the peripheral blood stream]. / Strahlenexposition des Personals bei der endovaskulären Brachytherapie (EVBT) mit Re-188 nach PTA im peripheren Stromgebiet.

Endovascular brachytherapy using a balloon catheter filled with Re-188 solution is a promising method for the prophylaxis of restenosis in peripheral blood circulation after percutaneous transluminal angioplasty (PTA) treatments. Thereby about 20 GBq Re-188 with a specific activity of about 5 GBq/ml are used. The high ionisation density of the beta radiation with high energy leads to selective irradiation of the blood vessel wall near the catheter, whereas the surrounding tissue remains almost unaffected. However the hospital staff has to carry out some work steps within close range to the high activity during preparation and therapy, causing a high risk of skin exposure, in particular at the hands. Estimations and measurements of the maximal local skin dose were made with thin-layered thermoluminescence dosimeters. It was assessed that the annual dose limit for skin of 500 mSv may be exceeded considerably when using conventional procedures and considering the expected number of 75 treatments per annum. By using the newly developed rhenium-188 application device "FlowMedical Application System" the exposure risk for the staff could be reduced drastically. The maximum skin dose of 76 mSv for the radiologist and of 50 mSv for the physicist was decreased to 2 mSv per treatment for both of them. Consequently, from the radiation protection point of view, the itm Rhenium-PTA is a safe method. Any exceeding of the dose limit can be prevented.

Endovascular brachytherapy in the femoropopliteal segment using 192Ir and 188Re.

This report presents a review of the literature on endovascular brachytherapy (EVBT) after percutaneous transluminal angioplasty (PTA) in the femoropopliteal segment. We summarize the pathophysiological changes induced by PTA and EVBT within the vessel wall, technical considerations regarding various radiation sources and their application, the impact of stents on the radial dose profile, recommendations for dosimetry of beta and gamma sources, results of experimental and clinical trials, and the medication required before, during, and after EVBT. We aim to help to identify patients who are eligible for EVBT, to choose an appropriate technical approach, and to initiate adequate antiplatelet and anticoagulant therapy.